Levetiracetam Aurobindo (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This binding modulates synaptic transmission, stabilizes neuronal membranes, and lowers excessive neuronal excitability, which together help prevent the spread of seizure activity.

The dosage of Levetiracetam Aurobindo is individualized. A qualified prescriber determines the appropriate dose based on the patient’s age, weight, renal function, seizure type, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for levetiracetam during pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess each case and discuss alternatives if necessary.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with older agents such as carbamazepine or valproic acid, levetiracetam has a relatively simple pharmacokinetic profile, fewer drug‑enzyme interactions, and does not require routine therapeutic drug monitoring. However, individual response varies, and clinicians consider seizure type, comorbidities and tolerability when selecting therapy.

Levetiracetam Aurobindo should be stored at or below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain potency.

The medication is administered orally, with or without food, as directed by the prescriber. Tablets (or the appropriate oral dosage form) should be swallowed whole with water. Patients should not crush or chew the tablets unless specifically instructed.

Serious adverse events include severe allergic reactions such as Stevens‑Johnson syndrome, marked skin rash, hematologic abnormalities, and significant mood changes including depression or suicidal thoughts. Any sudden or severe symptoms should prompt immediate medical evaluation.

Individuals with a known hypersensitivity to levetiracetam or any of its excipients should avoid the product. Patients with severe renal impairment may require dose adjustment or alternative therapy, and the drug should be used with caution in those with a history of mood disorders.